Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million

PRINCETON JUNCTION, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Alpha Capital Corp ("Alpha"), a global merchant bank, is pleased to announce that it has been retained as the exclusive financial advisor to CD8 Technology Services, LLC ("CD8 Technology") in connection with financing a real estate facility whose primary focus is developing and manufacturing biologic products for cell therapy. By eliminating barriers to entry, in terms of capital and time to build GMP capabilities at scale, this venture will expedite manufacturing for CD8 Technology's clients.

When completed, CD8 Technology will be among a handful of independent biologic contract manufacturing organizations in the United States. CD8 Technology has committed to providing a turn-key facility to Tevogen Bio (NASDAQ:TVGN) on a first-priority basis for its manufacturing needs to develop off-the-shelf, genetically unmodified T-cell therapeutics to treat infectious disease and cancers. Tevogen announced a $1b+ forecast earlier this month and through this facility, should be able to realize its revenue potential.

Alpha ...